Biomarin Pharmaceutical - Registered Shares Operating Income

As of the most recent data (June 2026), BMRN shows a operating income of $270M. That compares with $110B in the prior-year period — down 99.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMRN's operating income is now $270M (was $110B) — a 99.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biomarin Pharmaceutical - Registered Shares is outperforming or lagging.

Tracking BMRN's operating income over time shows whether Biomarin Pharmaceutical - Registered Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $270M That compares with $110B in the prior-year period — down 99.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Biomarin Pharmaceutical - Registered Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $270M) with ownership activity and broader fundamentals.

Biomarin Pharmaceutical - Registered Shares's operating income is $270M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.